Business Context and Reporting Period
This Form 8-K was filed by Tocagen Inc. (not Forte Biosciences, Inc.) on April 10, 2020. The report details the termination of a material definitive agreement regarding the company's debt obligations.
Key Financial Metrics
- Debt Prepayment: The company made a total prepayment of $4.8 million.
- Principal Repaid: $4.4 million of remaining outstanding term loan principal.
- Additional Costs: The prepayment covered all accrued and unpaid interest, the final payment on term loans, and all outstanding lender expenses.
- Interest Rate: The terminated loans accrued interest at the prime rate plus 3.75%, with a floor of 8.50%.
- Liquidity Impact: The filing does not provide specific cash balance or liquidity metrics following the transaction.
Material Changes
On April 10, 2020, Tocagen Inc. fully satisfied its obligations under the amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank. Consequently:
- The Loan Agreement was terminated.
- All liens on the company's assets, including intellectual property, were released.
- Restrictive covenants regarding asset disposal, mergers, acquisitions, and additional indebtedness were removed.
Outlook, Risks, and Management Commentary
The filing indicates that the company proactively chose to eliminate its debt obligations prior to the December 2022 maturity date. By removing the loan agreement, the company eliminated the risk of an immediate repayment trigger associated with events of default, such as a material adverse change. No forward-looking guidance or specific management commentary regarding future operations is included in this specific filing.
Investor Verification Checklist
- Verify the source of the $4.8 million cash used for the prepayment (e.g., cash on hand, new financing, or asset sales).
- Confirm the release of liens on intellectual property with the relevant lenders.
- Review the company's current cash runway post-prepayment to assess liquidity sustainability.
- Check for any new debt agreements or financing activities disclosed in subsequent filings.